- Home
- NDLS vs RLYB Comparison
NDLS vs RLYB Comparison
Compare NDLS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- RLYB
- Stock Information
- Founded
- NDLS 1995
- RLYB 2018
- Country
- NDLS United States
- RLYB United States
- Employees
- NDLS N/A
- RLYB N/A
- Industry
- NDLS Restaurants
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- RLYB Health Care
- Exchange
- NDLS Nasdaq
- RLYB Nasdaq
- Market Cap
- NDLS 29.8M
- RLYB 24.1M
- IPO Year
- NDLS 2013
- RLYB 2021
- Fundamental
- Price
- NDLS $0.70
- RLYB $0.63
- Analyst Decision
- NDLS Buy
- RLYB Hold
- Analyst Count
- NDLS 2
- RLYB 2
- Target Price
- NDLS $3.00
- RLYB N/A
- AVG Volume (30 Days)
- NDLS 2.1M
- RLYB 251.2K
- Earning Date
- NDLS 11-05-2025
- RLYB 11-06-2025
- Dividend Yield
- NDLS N/A
- RLYB N/A
- EPS Growth
- NDLS N/A
- RLYB N/A
- EPS
- NDLS N/A
- RLYB N/A
- Revenue
- NDLS $494,087,000.00
- RLYB $674,000.00
- Revenue This Year
- NDLS $1.19
- RLYB N/A
- Revenue Next Year
- NDLS N/A
- RLYB N/A
- P/E Ratio
- NDLS N/A
- RLYB N/A
- Revenue Growth
- NDLS N/A
- RLYB 12.71
- 52 Week Low
- NDLS $0.55
- RLYB $0.22
- 52 Week High
- NDLS $1.74
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- NDLS 49.29
- RLYB 57.15
- Support Level
- NDLS $0.65
- RLYB $0.54
- Resistance Level
- NDLS $0.80
- RLYB $0.65
- Average True Range (ATR)
- NDLS 0.13
- RLYB 0.05
- MACD
- NDLS -0.01
- RLYB 0.00
- Stochastic Oscillator
- NDLS 9.62
- RLYB 55.17
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.